EXTON, Pa., Feb. 28 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced it will present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference at 1:30 P.M. ET on Wednesday, March 5, 2008. The conference is being held at The W Hotel, in New York City.
ViroPharma's presentation will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conference.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com.
SOURCE ViroPharma Incorporated 02/28/2008
CONTACT: William C. Roberts, Vice President, Corporate Communications,
+1-610-321-6288, or Robert A. Doody, Manager, Corporate Communications,
+1-610-321-6290, both of ViroPharma Incorporated
Web site: http://www.viropharma.com